Subsequent preclinical studies have shown that pharmacological administration of recombinant FGF19 or FGF21, or antibodies directed against KLB/FGFR have potent, partially overlapping metabolic effects, including the lowering of blood glucose levels, hepatic fat content, and plasma bile acid and cholesterol levels, highlighting their potential as new drug candidates for the treatment of various obesity-related disorders, including T2D, NAFLD, cardiovascular disease, and cholestasis (15). Here, KLB is linked to type 2 diabetes mellitus.